Avenzo Therapeutics – a clinical-stage biotechnology company developing next-generation oncology therapeutics – announced the closing of an oversubscribed $150 million Series A-1 financing. This funding round included nine new investors and was led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital, with participation from additional new investors, including INCE Capital, TF Capital, Delos Capital, and Quan Capital. The total funding since the company’s founding in August 2022 is $347 million.
In connection with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors. Dr. Dupont brings over two decades of experience in oncology and other therapeutic areas, developing therapies and programs focused on addressing high unmet medical needs. Before joining Sofinnova Investments, Dr. Dupont served in key leadership roles at Atara Biotherapeutics, Gossamer Bio, Genentech/Roche, and OncoMed Pharmaceuticals.
The proceeds from the funding will be used to advance Avenzo’s emerging oncology pipeline, which is led by AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor being studied in an ongoing U.S.-based Phase 1 clinical study for the treatment of HR+/HER2- metastatic breast cancer and other advanced solid tumors.
KEY QUOTES:
“The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients. With the support of our new and existing investors, including OrbiMed, Foresite Capital, SR One, Lilly Asia Ventures and Surveyor Capital (a Citadel company), we are in a strong position to advance our potentially best-in-class CDK2 inhibitor, AVZO-021, expand our pipeline with additional assets, and continue to grow our team.”
– Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo
“We see significant opportunity with AVZO-021 and this team to advance potential best-in-class therapies for some of the most pressing needs in oncology today. I have been impressed by the progress Avenzo has made to date and look forward to supporting Athena and the Board as they advance their emerging oncology pipeline and grow their promising company.”
– Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments
